2021
DOI: 10.1002/rth2.12437
|View full text |Cite
|
Sign up to set email alerts
|

Physical activity and bleeding outcomes among people with severe hemophilia on extended half‐life or conventional recombinant factors

Abstract: Background Few have assessed physical activity (PA) and annual bleed rates (ABRs) among people with hemophilia on extended half‐life (EHL) factors (recombinant factor VIII Fc [rFVIIIFc]/recombinant factor IX Fc [rFIXFc]) and conventional factors (recombinant factor VIII [rFVIII]/recombinant factor IX [rFIX]). Objective To assess changes in PA and ABR at consecutive annual visits in individuals with severe hemophilia A and B (HA/HB) on prophylactic treatment with rFVIIIF… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
18
0
1

Year Published

2021
2021
2024
2024

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 6 publications
(19 citation statements)
references
References 18 publications
0
18
0
1
Order By: Relevance
“…A large number of retrospective real-world studies have confirmed the efficacy of efmoroctocog alfa in the prophylaxis of bleeding observed in phase III clinical trials. The following discussion, however, only focuses on those involving > 30 PTPs from one or more European countries [31,[36][37][38][39][40][41][42][43][44][47][48][49] or the USA [50][51][52].…”
Section: Real-world Experiencementioning
confidence: 99%
See 1 more Smart Citation
“…A large number of retrospective real-world studies have confirmed the efficacy of efmoroctocog alfa in the prophylaxis of bleeding observed in phase III clinical trials. The following discussion, however, only focuses on those involving > 30 PTPs from one or more European countries [31,[36][37][38][39][40][41][42][43][44][47][48][49] or the USA [50][51][52].…”
Section: Real-world Experiencementioning
confidence: 99%
“…Table 5 Real-world effectiveness of prophylaxis with efmoroctocog alfa versus other recombinant FVIII products in patients with haemophilia A: results of multicentre, retrospective, chart-review studies from Europe and the USA Pts had been treated for ≥ 8 wks [36,38,51] or ≥ 6 months [52] at the time of data collection ABR annualized bleeding rate, BL baseline, CFC clotting factor consumption, IF injection frequency, IU international unit, NR not reported, pts patients, rFVIII recombinant FVIII, rFVIII-FS sucrose-formulated rFVIII, wk(s) week(s) *p = 0.001 vs rFVIII a Median values, except for Shrestha et al [52] The efficacy and safety of efmoroctocog alfa for the longterm prophylaxis, acute treatment and perioperative management of bleeding in male PTPs of all ages with severe haemophilia A was initially demonstrated in phase III clinical trials, including two parent studies (A-LONG and Kids A-LONG) and their extension study (ASPIRE) (Sects. 3.1, 4).…”
Section: Dosage and Administrationmentioning
confidence: 99%
“…Further, well supervised sport therapies do not cause higher bleeding rates, emphasizing that regular PA may even reduce the frequency of bleeding events 11,16,17 . Prior literature showed that recent replacement strategies with extended half‐life factors positively impact PA as the trough level is substantially increased 16 . Hence, an expert consensus exists that planned and professionally supervised PA should be recommended for PwH 10–13,18 …”
Section: Introductionmentioning
confidence: 99%
“…These changes ultimately improve the patients’ quality of life. Further, well supervised sport therapies do not cause higher bleeding rates, emphasizing that regular PA may even reduce the frequency of bleeding events 11,16,17 . Prior literature showed that recent replacement strategies with extended half‐life factors positively impact PA as the trough level is substantially increased 16 .…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation